Sustained release carriers used to delivery bone morphogenetic proteins in the bone healing process

Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia

Volumn 37, Issue 3, 2008, Pages 181-187

  Issa, J P M ^a   Bentley, M V L B ^a   Iyomasa, M M ^a   Sebald, W ^b   De Albuquerque, R F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43749119608     PISSN: 03402096     EISSN: 14390264     Source Type: Journal    
DOI: 10.1111/j.1439-0264.2007.00824.x     Document Type: Article

References (70)

1. Akamaru, T., D. Suh, S. D. Boden, H. S. Kim, A. Minamide, and J. Louis‐Ugbo, 2003: Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein‐2 for posterolateral spine fusion. Spine 28, 429–434.
2. Behrevesh, E., A. Yasko, P. S. Engel, and A. Mikos, 1999: Synthetic biodegradable polymers for orthopaedic applications. Clin. Orthop.Relat. Res. 41, S118–S129.
3. Bhattarai, N., H. R. Ramay, J. Gunn, F. A. Matsen, and M. Zhang, 2005: PEG‐grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J. Control. Release 103, 609–624.
4. Den Boer, F. C., B. W. Wippermann, T. J. Blokhuis, P. Patka, F. C. Bakker, and H. J. Haarman, 2003: Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein‐1 or autologous bone marrow. J. Orthop. Res. 21, 521–528.
5. Bohner, M., and G. Baroud, 2005: Injectability of calcium phosphate pastes. Biomaterials 26, 1553–1563.
6. Bolander, M. E., and G. Balian, 1986: The use of demineralized bone matrix in repair of segmental defects. J. Bone Jt. Surg. 68A, 1264–1274.
7. Bonacucina, G., G. F. Palmieri, and D. Q. Craig, 2005: Rheological and dielectric characterization of monoolein/water mesophases in the presence of a peptide drug. J. Pharm. Sci. 94, 2452–2462.
8. Boontheekul, T., and D. J. Mooney, 2003: Protein‐based signaling systems in tissue engineering. Curr. Opin. Biotechnol. 14, 559–565.
9. Bouxsein, M. L., T. J. Turek, C. A. Blake, D. D′Augusta, X. Li, M. Stevens, H. J. Seeherman, and J. M. Wozney 2001: Recombinant human bone morphogenetic protein‐2 accelerates healing in a rabbit ulnar osteotomy model. J. Bone. Joint. Surg. 83‐A, 1219–1230.
10. Boyd, B. J., D. V. Whittaker, S. M. Khoo, and G. Davey, 2006: Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int. J. Pharm. 309, 218–226.
11. Clokie, C. M., and M. R. Urist, 2000: Bone morphogenetic protein excipients: comparative observations on poloxamer. Plast. Reconstr. Surg. 105, 628–637.
12. Cullinane, D. M., S. A. Lietman, N. Inoue, L. W. Deitz, and E. Y. Chao, 2002: The effect of recombinant human osteogenic protein‐1 (bone morphogenetic protein‐7) impregnation on allografts in a canine intercalary bone defect. J. Orthop. Res. 20, 1240–1245.
13. Damien, C. J., J. R. Parsons, A. B. Prewett, D. C. Rietveld, and M. C. Zimmerman, 1994: Investigation of an organic delivery system for demineralized bone matrix in a delayed‐healing cranial defect model. J. Biomed. Mater. Res. 28, 553–561.
14. Di Silvio, L., N. Gurav, MV. Kayser, M. Braden, and S. Downes, 1994a: Biodegradable microspheres: a new delivery system for growth hormone. Biomaterials 15, 931–936.
15. Di Silvio, L., M. V. Kayser, and S. Downes, 1994b: Validation and optimization of a polymer system for potential use as a controlled drug delivery system. Clin. Mater. 16, 91–98.
16. Downes, S., R. S. Archer, M. V. Kayser, M. P. Patel, and M. Braden, 1994: The regeneration of articular cartilage using a new polymer system. J. Materials. Sci. 5, 88–95.
17. Ducheyne, P., A. El‐Ghannam, and I. Shapiro, 1994: Effect of bioactive glass templates on osteoblast proliferation and in vitro synthesis of bone‐like tissue. J. Cell. Biochem. 56, 162–167.
18. Gao, T. J., T. S. Lindholm, B. Kommonen, P. Ragni, A. Paronzini, T. C. Lindholm, T. Jamsa, and P. Jalovaara, 1996: Enhanced healing of segmental tibial defects in sheep by a composite bone substitute composed of tricalcium phosphate cylinder, bone morphogenetic protein, and type IV collagen. J. Biomed. Mater. Res. 32, 505–512.
19. Hollinger, J. O., and K. Leong, 1996: Poly(α‐hydroxy acids): Carriers for bone morphogenetic proteins. Biomaterials 17, 187–194.
20. Hollinger, J. O., J. P. Schmitz, J. W. Mizgala, and C. Hassler, 1989: An evaluation of two configurations of tricalcium phosphate for treating craniotomies. J. Biomed. Mater. Res. 23, 17–29.
21. Hubbell, J. A., 2003: Materials as morphogenetic guides in tissue engineering. Curr. Opin. Biotechnol. 14, 551–558.
22. Isobe, M., Y. Yamazaki, M. Mori, K. Ishihara, N. Nakabayashi, and T. Amagasa, 1999: The role of recombinant human bone morphogenetic protein‐2 in PLGA capsules at an extraskeletal site of the rat. J. Biomed. Mater. Res. 45, 36–41.
23. Kannan, R. Y., H. J. Salacinski, K. Sales, P. Butler, and A. M. Seifalian, 2005: The roles of tissue engineering and vascularisation in the development of micro‐vascular networks: a review. Biomaterials 26, 1857–1875.
24. Kao, H. J., H. R. Lin, Y. L. Lo, and S. P. Yu, 2006: Characterization of pilocarpine‐loaded chitosan/carbopol nanoparticles. J. Pharm. Pharmacol. 58, 179–186.
25. Katz, R. W., J. O. Hollinger, and A. H. Reddi, 1993: The functional equivalence of demineralized bone and tooth matrices in ectopic bone induction. J. Biomed. Mater. Res. 27, 239–245.
26. Kawamura, M., H. Iwata, K. Sato, and T. Miura, 1987: Chondroosteogenetic response to crude bone matrix proteins bound to hydroxyapatite. Clin. Orthop. Relat Res. 217, 281–292.
27. Kofuji, K., Y. Murata, and S. Kawashima, 2005: Sustained insulin release with biodegradation of chitosan gel beads prepared by copper ions. Int. J. Pharmacol. 303, 95–103.
28. Kokubo, S., M. Mochizuki, S. Fukushima, T. Ito, K. Nozaki, T. Iwai, K. Takahashi, S. Yokota, K. Miyata, and N. Sasaki, 2004: Long‐term stability of bone tissues induced by an osteoinductive biomaterial, recombinant human bone morphogenetic protein‐2 and a biodegradable carrier. Biomaterials 25, 1795–1803.
29. Kroese‐Deutman, H. C., P. Q. Ruhe, P. H. Spauwen, and J. A. Jansen, 2005: Bone inductive properties of rhBMP‐2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits. Biomaterials 26, 1131–1138.
30. Lakshmi, S., D. S. Katti, and C. T. Laurencin, 2003: Biodegradable polyphosphazenes for drug delivery applications. Adv. Drug. Deliv. Rev. 55, 467–482.
31. Lane, J. M., A. W. Yasko, and E. Tomin, 1999: Bone marrow and recombinant human bone morphogenetic protein‐2 in osseous repair. Clin. Orthop. Relat. Res. 361, 216–227.
32. Laurencin, C. T., M. E. Norman, H. M. Elgendy, S. F. El‐Amin, S. Pucher, A. Ambrosio, and H. R. Alcock, 1993: Polyphosphozanes–a novel biocompatible bioerodible polymer for bone regeneration. Trans. Orthop. Res. Soc. 18, 480–485.
33. Lee, J., and I. W. Kellaway, 2000b: Buccal permeation of [D‐Ala 2, D‐Leu 5 ] enkephalin from liquid crystalline phases of glyceryl monooleate. Int. J. Pharm. 195, 35–38.
34. Lee, S. C., M. Shea, M. A. Battle, K. Kozitza, E. Ron, T. Turek, R. G. Schaub, and W. C. Hayes, 1994: Healing of large segmental defects in rat femurs is aided by rhBMP‐2 in PLGA matrix. J. Biomed. Mater. Res. 28, 1149–1156.
35. Lee, J., S. A. Young, and I. W. Kellaway, 2001: Water quantitatively induces the mucoadhesion of liquid crystalline phases of glyceryl monoleate. J. Pharm. Pharmacol. 53, 629–636.
36. Lee, S. J., S. W. Kim, H. Chung, Y. T. Park, Y. W. Choi, Y. W. Choi, Y. H. Cho, and M. S. Yoon, 2005: Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel. Chemotherapy 51, 311–318.
37. Li, R. H., and J. M. Wozney, 2001: Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 19, 255–265.
38. Li, R. H., M. L. Bouxsein, C. A. Blake, D. D‘Augusta, H. Kim, X. J. Li, J. M. Wozney, and H. J. Seeherman, 2003: rhBMP‐2 injected in a calcium phosphate paste (alpha‐BSM) accelerates healing in the rabbit ulnar osteotomy model. J. Orthop. Res. 21, 997–1004.
39. Lindholm, T. A., and T. J. Gao, 1993: Functional carriers for bone morphogenetic proteins. Ann. Chir. Gynaecol. 82, 3–12.
40. Lucas, P. A., C. Laurencin, G. T. Syftestad, A. Domb, V. M. Goldberg, A. I. Caplan, and R. Langer, 1990: Ectopic induction of cartilage and bone by water soluble proteins from bovine bone using a polyanhydride delivery vehicle. J. Biomed. Mater. Res. 24, 901–911.
41. Mikos, A. G., Y. Bao, L. G. Cima, D. E. Ingber, J. P. Vacanti, and R. Langer, 1993: Preparation of poly(glycolic acid) bonded fiber structures for cell attachment and transplantation. J. Biomed. Mater. Res. 27, 183–189.
42. Miller, E. J., and R. K. Rhodes, 1982: Preparation and characterization of different types of collagen. Methods Enzymol. 82A, 33–64.
43. Miyamoto, S., K. Takaoka, T. Okada, H. Yoshikawa, J. Hashimoto, S. Suzuki, and K. Ono, 1992: Evaluation of polylactic acid homopolymers as carriers for bone morphogenetic protein. Clin. Orthop. Relat. Res. 278, 274–285.
44. Murakami, N., N. Saito, H. Horiuchi, T. Okada, K. Nozaki, and K. Takaoka, 2002: Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein‐2 (rhBMP‐2) and a synthetic polymer. J. Biomed. Mater. Res. 62, 169–174.
45. Ohgushi, H., M. Okumura, S. Tamai, E. C. Shors, and A. I. Caplan, 1993: Marrow cell‐induced osteogenesis in porous hydroxyapatite and tricalcium phosphate: a comparative histomorphometric study of ectopic bone formation. J. Biomed. Mater. Res. 24, 1563–1570.
46. Patel, M. P., and M. Braden, 1989: Cross‐linking and ring opening during polymerization of heterocyclic methacrylates and acrylates. Biomaterials 10, 277–280.
47. Patel, M. P., and M. Braden, 1991a: Heterocyclic methacrylates for clinical applications I. Mechanical properties. Biomaterials 12, 645–648.
48. Patel, M. P., and M. Braden, 1991b: Heterocyclic methacrylates for clinical applications II. Room temperature polymerizing systems for clinical use. Biomaterials 12, 649–652.
49. Patel, M. P., and M. Braden, 1991c: Heterocyclic methacrylates for clinical applications III. Water absorption characteristics. Biomaterials 12, 653–657.
50. Patel, MP., M. Braden, and K. W. M. Davy, 1987: Polymerization shrinkage of methacrylate esters. Biomaterials 8, 53–56.
51. Patel, M. P., M. Braden, and S. Downes, 1995: Heterocyclic methacrylate‐based drug release polymer system. J. Mater. Sci. 5, 338–339.
52. Del Real, R. P., J. G. Wolke, M. Vallet‐Regi, and J. A. Jansen, 2002: A new method to produce macropores in calcium phosphate cements. Biomaterials 23, 3673–3680.
53. Renier, M. L., and D. H. Kohn, 1997: Development and characterization of a biodegradable polyphosphate. J. Biomed. Mater. Res. 34, 95–104.
54. Richards, M., B. I. Dahiyat, D. M. Arm, P. R. Brown, and K. W. Leong, 1991: Evaluation of polyphosphates and polyphosphonates as degradable biomaterials. J. Biomed. Mater. Res. 25, 1151–1167.
55. Ripamonti, U., and A. H. Reddi, 1992: The critical role of geometry of porous hydroxyapatite delivery system in induction of bone by osteogenin, a bone morphogenetic protein. Matrix 12, 202–212.
56. Schmokel, H. G., F. E. Weber, G. Seiler, B. Von Rechenberg, J. C. Schense, P. Schawalder, and J. Hubbell, 2004: Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein‐2 delivered from a fibrin matrix. Vet. Surg. 33, 112–118.
57. Shah, J. C., Y. Dadhale, and D. M. Chilukuri, 2001: Cubic phase gels as drug delivery systems. Adv. Drug. Deliv. Rev. 47, 229–250.
58. Sigurdssan, T., M. B. Lee, K. Kubota, T. J. Turek, J. M. Wozney, and U. M. E. Wikesjo, 1995: Periodontal repair in dogs: Recombinant human bone morphogenetic protein‐2 significantly enhances periodontal regeneration. J. Periodontol. 66, 131–138.
59. Sigurdsson, T. J., L. Nygaard, D. N. Tatakis, E. Fu, T. J. Turek, L. Jin, J. M. Wozney, and U. M. E. Wikesjo, 1996: Periodontal repair in dogs: Evaluation of rhBMP‐2 carriers. Int. J. Periodont. Rest. Dent. 16, 525–537.
60. Stupp, S. L., and G. W. Ciegler, 1992: Organoapatites: materials for artificial bone. I: synthesis and microstructure. J. Biomed. Mater. Res. 26, 169–183.
61. Tada, H., M. Hatoko, A. Tanaka, M. Kuwahara, K. Mashiba, S. Yurugi, H. Iioka, and K. Niitsuma, 2002: Preshaped hydroxyapatite tricalcium‐phosphate implant using three‐dimensional computed tomography in the reconstruction of bone deformities of craniomaxillofacial region. J. Craniofac. Surg. 13, 287–292.
62. Takaoka, K., H. Nakahara, H. Yoshikawa, K. Masuhara, T. Tsuda, and K. Ono, 1988: Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein. Clin. Orthop. Relat. Res. 234, 250–254.
63. Takita, H., J. W. Vehof, J. A. Jansen, M. Yamamoto, Y. Tabata, M. Tamura, and Y. Kuboki, 2004: Carrier dependent cell differentiation of bone morphogenetic protein‐2 induced osteogenesis and chondrogenesis during the early implantation stage in rats. J. Biomed. Mater. Res. 71, 181–189.
64. Talwar, R., L. Di Silvio, F. J. Hughes, and G. N. King, 2001: Effects of carrier release kinetics on bone morphogenetic protein‐2‐induced periodontal regeneration in vivo. J. Clin. Periodontol. 28, 340–347.
65. Tretinnikov, O. N., K. Kato, and Y. Ikada, 1994: In vitro hydroxyapatite deposition onto a film surface grafted with organophosphate film. J. Biomed. Mater. Res. 28, 1365–1373.
66. Urist, M., 1965: Bone: formation by autoinduction. Science 150, 893–899.
67. Vehof, J. W., H. Takita, Y. Kuboki, P. H. Spauwen, and J. A. Jansen, 2002: Histological characterization of the early stages of bone morphogenetic protein‐induced osteogenesis. J. Biomed. Mater. Res. 61, 440–449.
68. Vert, M., S. Li, and H. Garreau, 1992: New insights on the degradation of bio‐resorbable polymeric devices based on lactic and glycolic acids. Clin. Mater. 10, 3–8.
69. Wang, Y., Y. M. Kim, and R. Langer, 2003: In vivo degradation characteristics of poly(glycerol sebacate). J. Biomed. Mater. Res. A 66, 192–197.
70. Yudell, R. M., and M. S. Block, 2000: Bone gap healing in the dog using recombinant human bone morphogenetic protein‐2. J. Oral Maxillofac. Surg. 58, 761–766.